PR vs REGN · P/E 21, rev $5.00B vs P/E 14, rev $14.34B
Permian Resources Corporation (PR) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Permian Resources Corporation (PR) is a oil & gas e&p company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported PR revenue for 2024-12-31 was $5.00B. Net income was $1.25B. Revenue was up 60.2% from 2023-12-31 to 2024-12-31. PR currently screens at market cap $15.99B and trailing P/E 20.9.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
PR currently screens at market cap $15.99B and trailing P/E 20.9. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the PR and REGN stock pages for the full models.
Not investment advice.